Evidence map›Paper›PMID 28635356›Full record

ArticleThe Journal of international medical research2017

Simultaneous ABO-incompatible living-donor liver transplantation and splenectomy without plasma exchange in China: Two case reports.

Guoyong Chen, Janjun Sun, Sidong Wei, Yongfeng Chen, Gaofeng Tang, Zhantao Xie, Huaen Xu, Janbin Chen, Huibo Zhao, Zhenhua Yuan and 4 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of international medical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Guoyong Chen1 Department of Hepatobiliary and Pancreatic Surgery, People's Hospital, Zhengzhou University, Zhengzhou, China.
Janjun Sun1 Department of Hepatobiliary and Pancreatic Surgery, People's Hospital, Zhengzhou University, Zhengzhou, China.
Sidong Wei1 Department of Hepatobiliary and Pancreatic Surgery, People's Hospital, Zhengzhou University, Zhengzhou, China.
Yongfeng Chen1 Department of Hepatobiliary and Pancreatic Surgery, People's Hospital, Zhengzhou University, Zhengzhou, China.
Gaofeng Tang1 Department of Hepatobiliary and Pancreatic Surgery, People's Hospital, Zhengzhou University, Zhengzhou, China.
Zhantao Xie1 Department of Hepatobiliary and Pancreatic Surgery, People's Hospital, Zhengzhou University, Zhengzhou, China.
Huaen Xu1 Department of Hepatobiliary and Pancreatic Surgery, People's Hospital, Zhengzhou University, Zhengzhou, China.
Janbin Chen1 Department of Hepatobiliary and Pancreatic Surgery, People's Hospital, Zhengzhou University, Zhengzhou, China.
Huibo Zhao1 Department of Hepatobiliary and Pancreatic Surgery, People's Hospital, Zhengzhou University, Zhengzhou, China.
Zhenhua Yuan1 Department of Hepatobiliary and Pancreatic Surgery, People's Hospital, Zhengzhou University, Zhengzhou, China.
Weiwei Wang1 Department of Hepatobiliary and Pancreatic Surgery, People's Hospital, Zhengzhou University, Zhengzhou, China.
Guangbo Liu1 Department of Hepatobiliary and Pancreatic Surgery, People's Hospital, Zhengzhou University, Zhengzhou, China.
Bing Wang1 Department of Hepatobiliary and Pancreatic Surgery, People's Hospital, Zhengzhou University, Zhengzhou, China.
Biao Niu1 Department of Hepatobiliary and Pancreatic Surgery, People's Hospital, Zhengzhou University, Zhengzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ABO-incompatible (ABO-i) living-donor liver transplantation (LDLT) is performed if an ABO-compatible graft cannot be obtained. However, a perfect desensitization protocol has not been established worldwide, especially for simultaneous ABO-i LDLT and splenectomy. We herein report two cases of ABO-i LDLT. To the best of our knowledge, this is the first case report of ABO-i LDLT in an adult patient in China. Splenectomy and T-cell-targeted immunosuppression (basiliximab) was used to overcome the blood group barrier in these recipients. The patients had good graft function without signs of antibody-mediated rejection throughout the 12-month follow-up. Thus, ABO-i LDLT with splenectomy is undoubtedly life-saving when an ABO-compatible graft cannot be obtained for patients in critical condition.

Indexed as

Liver TransplantationLiving DonorsPlasma ExchangeSplenectomyABO Blood-Group SystemAdultAnticoagulantsChinaFemaleFollow-Up StudiesHumansMaleABO Blood-Group SystemAnticoagulantsABO-incompatible transplantationliver transplantationliving-donor transplantationsplenectomytreatment

Identifiers

PMID28635356
PMCPMC5805207

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.